Cuba vs Norway: Life science patents granted, by technology
Cuba
17 patents
in 2023
Norway
16 patents
in 2023
Cuba rank
31st
Norway rank
32nd
Life science patents granted, by technology over time
- Cuba
- Norway
How they compare
Cuba currently reports 17 patents against 16 patents in Norway, a difference of 1 patents.
That makes Cuba's figure about 1.1 times Norway's.
The two have swapped places 3 times across 26 shared years of data; in 1987 it was Norway ahead.
Cuba ranks 31st and Norway ranks 32nd of 65 countries.
Norway has averaged higher in every one of the 5 decades both report.
Head to head by decade
| Decade | Cuba | Norway | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 2 patents | 103.5 patents | 101.5 patents | Norway |
| 1990s | 1 patents | 176 patents | 175 patents | Norway |
| 2000s | 9.38 patents | 232.88 patents | 223.5 patents | Norway |
| 2010s | 27.5 patents | 170.1 patents | 142.6 patents | Norway |
| 2020s | 20.25 patents | 26.75 patents | 6.5 patents | Norway |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher life science patents granted, by technology, Cuba or Norway?
- Cuba, at 17 patents against 16 patents in Norway as of 2023.
- What is the difference in life science patents granted, by technology between Cuba and Norway?
- 1 patents, with Cuba ahead.
- How many years of comparable data are there for Cuba and Norway?
- 26 years are reported by both, from 1987 to 2023.
- How do Cuba and Norway rank globally for life science patents granted, by technology?
- Cuba ranks 31st and Norway ranks 32nd of 65 countries.
- Where does this data come from?
- World Intellectual Property Organization (WIPO) (2025) β processed by Our World in Data, published as Life science patents granted, by technology. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of pharmaceutical patents granted by the filing office in a given year. Pharmaceutical patents typically cover new drugs, biological treatments or vaccines.